SANTA CRUZ BIOTECHNOLOGY, INC.

FAS-L (Alf2.1): sc-73552



The Power to Question

BACKGROUND

Cytotoxic T lymphocyte (CTL)-mediated cytotoxicity constitutes an important component of specific effector mechanisms in immuno-surveillance against virus-infected or transformed cells. Two mechanisms appear to account for this activity, one of which is the perforin-based process. Independently, a FAS-based mechanism involves the transducing molecule FAS (also designated APO-1) and its ligand (FAS-L). The human FAS protein is a cell surface glyco-protein that belongs to a family of receptors that includes CD40, nerve growth factor receptors and tumor necrosis factor receptors. The FAS antigen is expressed on a broad range of lymphoid cell lines, certain of which undergo apoptosis in response to treatment with antibody to FAS. These findings strongly imply that targeted cell death is potentially mediated by the intercellular interactions of FAS with its ligand or effectors, and that FAS may be critically involved in CTL-mediated cytotoxicity.

REFERENCES

- Henkart, P.A. 1985. Mechanism of lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 3: 31-58.
- Drappa, J., et al. 1993. The FAS protein is expressed at high levels on CD4+CD8+ thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr. Proc. Natl. Acad. Sci. USA 90: 10340-10344.
- 3. Hanabuchi, S., et al. 1994. FAS and its ligand in a general mechanism of T cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 91: 4930-4934.
- Lopatinskaya, L., et al. 2006. Mediators of apoptosis FAS and FAS-L predict disability progression in multiple sclerosis over a period of ten years. Mult. Scler. 12: 704-709.
- Xie, X.Z., et al. 2006. Expression of Gastrin, Somatostatin, PCNA and FAS-L in the mucosa of gastric antrum of children with chronic gastritis and duodenal ulcer. Zhonghua Er Ke Za Zhi 44: 774-777.
- Kopinski, P., et al. 2006. Apoptosis of alveolar lymphocytes in sarcoidosis and in control group is more frequent in smokers than in nonsmoking persons. Prz. Lek. 63: 841-847.
- 7. Chen, A., et al. 2007. Depleting intratumoral CD4+CD25+ regulatory T cells via FAS-L protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res. 67: 1291-1298.
- 8. Manicassamy, S., et al. 2007. The critical role of protein kinase C- θ in FAS/ FAS ligand-mediated apoptosis. J. Immunol. 178: 312-319.
- Eidsmo, L., et al. 2007. FAS-L and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to *Leishmania* major. Am. J. Pathol. 170: 227-239.

CHROMOSOMAL LOCATION

Genetic locus: FASLG (human) mapping to 1q23.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

FAS-L (Alf2.1) is a mouse monoclonal antibody raised against recombinant soluble active extracellular domain of human FAS ligand.

PRODUCT

Each vial contains 200 $\mu g~lg G_1$ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Available as phycoerythrin conjugate for flow cytometry, sc-73552 PE, 100 tests.

APPLICATIONS

FAS-L (Alf2.1) is recommended for detection of FAS-L of human origin by immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 μ g per 1 x 10⁶ cells).

Suitable for use as control antibody for FAS-L siRNA (h): sc-29313, FAS-L shRNA Plasmid (h): sc-29313-SH and FAS-L shRNA (h) Lentiviral Particles: sc-29313-V.

Molecular Weight of soluble FAS-L: 26 kDa.

Molecular Weight of FAS-L membrane: 40 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 2) Immunofluorescence: use goat antimouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.